

**G**CONNEQT

ASX ANNOUNCEMENT 31 October 2022

# **Cleansing Statement**

<u>CardieX Limited</u> (ASX: CDX) (**CardieX**, the **Company**) advises that on 28 October 2022, it issued a total of 119,048 Fully Paid Ordinary Shares without disclosure to the recipients under Part 6D.2 of the Corporations Act 2001 (Cth) (the **Corporations Act**).

The Company hereby gives notice under Section 708A(5) of the Corporations Act, and for all other purposes, that:

- (a) the company has issued the Securities without disclosure to the recipients under Part 6D.2 of the Corporations Act;
- (b) as at the date of this notice, the Company has complied with the provisions of:
  - a. Chapter 2M of the Corporations Act as they apply to the Company; and
  - b. Section 674 of the Corporations Act; and
- (c) As at the date of this notice there is no information
  - a. That has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules; and
  - b. That investors and their professional advisers would reasonably require for the purpose of making an information assessment of:
    - i. the assets and liabilities, financial position and performance, profits and losses and prospects of the body; or
    - ii. the rights and liabilities attaching to the relevant securities.

to the extent to which it is reasonable for investors and their professional advisers to expect to find the information in a disclosure document.

Approved by the Board of Directors and Released by Jarrod White, Director.

For more information, please contact:

# **Investor Relations**

Rod Hinchcliffe rod.hinchcliffe@mcpartners.com.au

# **Media Relations**

Melissa Hamilton melissa.hamilton@mcpartners.com.au

# **Investor Relations – USA**

Matt Selinger
Managing Director, Integrous Communications
mselinger@integcom.com

# **About CardieX**

CardieX is a global health technology company. Its <u>ATCOR</u> subsidiary is a world leader in medical devices for hypertension, cardiovascular disease, and other vascular health disorders based on the Company's "gold standard" SphygmoCor® central blood pressure technology. CardieX's <u>CONNEQT</u> subsidiary develops and markets medical devices, digital solutions, and wearables for home health, primary clinician, and other healthcare channels. CardieX is listed on the Australian Stock Exchange (ASX:CDX).